913 results on '"Visakorpi, Tapio"'
Search Results
152. Amplification and Overexpression of Elongin C Gene Discovered in Prostate Cancer by cDNA Microarrays
153. Gonadoblastoma and Dysgerminoma Associated with XY Gonadal Dysgenesis in an Adolescent with Chronic Renal Failure: A Case of Frasier Syndrome
154. Somatic mutation analysis of MYH11 in breast and prostate cancer
155. Androgen regulation of the androgen receptor coregulators
156. PARP-1 regulates DNA repair factor availability.
157. PREDICTORS OF BIOLOGICAL AGGRESSIVENESS OF PROSTATE SPECIFIC ANTIGEN SCREENING DETECTED PROSTATE CANCER
158. Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data
159. Additional file 1: of Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas
160. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
161. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients
162. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
163. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status
164. Abstract A077: Chromatin state alterations in human prostate cancer progression
165. Abstract B017: PARP-1 and E2F1 collaborate to transcriptionally regulate DNA repair factor availability
166. Abstract B040: Differential impact of RB status on E2F1 reprogramming in human cancer
167. Abstract A020: Integrative analysis of the proteome in primary and advanced prostate cancer
168. Abstract IA03: Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer
169. Abstract B077: 3D reconstruction and machine learning-based analysis of prostate cancer from histologic images
170. Proteomics of prostate cancer – revealing how cancer cells master their messy genomes
171. Abstract 2476: Discovery of an androgen-responsive long noncoding RNA that associates with progression of ERG-overexpressing prostate cancers
172. Abstract 1802: Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
173. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer
174. Comparative analysis of tissue reconstruction algorithms for 3D histology
175. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression
176. Endocrinology of prostate cancer
177. The expression of AURKA is androgen regulated in castration-resistant prostate cancer
178. Differential impact of RB status on E2F1 reprogramming in human cancer
179. Amplification and Overexpression of p40 Subunit of Eukaryotic Translation Initiation Factor 3 in Breast and Prostate Cancer
180. Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers
181. Integrated clinical, whole genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer
182. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer
183. Abstract LB-085: RB loss-induced genome wide E2F1 reprogramming drive advanced prostate cancer
184. Abstract LB-086: PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity
185. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas
186. PD40-06 A FOUR-KALLIKREIN PANEL IN PREDICTING HIGH-GRADE PROSTATE CANCER ON BIOPSY: AN INDEPENDENT REPLICATION FROM THE FINNISH SECTION OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER.
187. Abstract A08: PARP1-mediated E2F1 regulation of DNA repair capacity
188. Analysis of spatial heterogeneity in normal epithelium and preneoplastic alterations in mouse prostate tumor models
189. The Molecular Evolution of Castration-resistant Prostate Cancer
190. Duodecim ja Suomen Lääketieteen Säätiö hakevat uusia tutkimusavauksia
191. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer
192. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations
193. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs
194. Mapping of the chromosomal amplification 1p21-22 in bladder cancer
195. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer
196. miR-32 promotes replicative changes in prostate epithelium in vivo
197. Next generation sequencing panels to predict response to hormonal therapy in prostate cancer
198. Chromatin relaxation is a feature of advanced prostate cancer
199. Expression of a novel androgen-regulated long noncoding RNA correlates with progression-free survival in prostate cancer patients
200. Histological modeling of prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.